-
公开(公告)号：EP4450127A2
公开(公告)日：2024-10-23
申请号：EP24194825.6
申请日：2019-07-22
IPC分类号： A61P3/10
摘要： The present invention provides methods of treating type 2 diabetes (T2D) using a novel dosing regimen of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is about 2.5:1 to about 10:1 GIP to GLP-1. Furthermore, the present invention provides methods of treating T2D using a novel dosing regimen of a GIP:GLP-1 Peptide having a GIP:GLP-1 receptor agonist potency ratio that is about 2.5:1 to about 5:1 GIP to GLP-1. Also, the present invention provides methods of inducing T2D remission using a novel dosing regimen of a GIP:GLP-1 Peptide. The present invention also provides methods of treating obesity using a novel dosing regimen of a GIP:GLP-1 Peptide.
-
公开(公告)号：EP3083668A1
公开(公告)日：2016-10-26
申请号：EP14821985.0
申请日：2014-12-11
IPC分类号： C07K14/605
CPC分类号： C07K14/605 , A61K38/00
摘要： The present invention provides a novel compound useful in the treatment of hypoglycemia.
摘要翻译： 本发明提供了在低血糖的治疗中有用的新型化合物。
-
公开(公告)号：EP1753780B1
公开(公告)日：2008-03-19
申请号：EP05749168.0
申请日：2005-05-19
发明人： BOKVIST, Bengt Krister, Lilly Forschung GmbH , CUMMINS, Robert, Chadwick , GLAESNER, Wolfgang , GROMADA, Jesper Lindgren, Lilly Forschung GmbH , MAYER, John, Philip , ZHANG, Lianshan , ALSINA-FERNANDEZ, Jorge
IPC分类号： C07K14/575
CPC分类号： C07K14/57563
摘要： The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
-
公开(公告)号：EP1781694A1
公开(公告)日：2007-05-09
申请号：EP05784310.4
申请日：2005-08-11
发明人： BOKVIST, Bengt, Krister, Lilly Forschung GmbH , MAYER, John, Philip , ZHANG, Lianshan , ALSINA-FERNANDEZ, Jorge , VICK, Andrew, Mark
IPC分类号： C07K14/435 , A61K38/22
CPC分类号： A61K47/60
摘要： The present invention encompasses PEGylated peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
-
公开(公告)号：EP4007593A1
公开(公告)日：2022-06-08
申请号：EP20758004.4
申请日：2020-07-29
-
公开(公告)号：EP3242887B1
公开(公告)日：2019-08-14
申请号：EP16703620.1
申请日：2016-01-05
IPC分类号： C07K14/575 , C07K14/605 , A61K38/26
-
公开(公告)号：EP2515927B1
公开(公告)日：2014-08-06
申请号：EP10799178.8
申请日：2010-12-15
IPC分类号： A61K38/17 , A61K38/26 , C07K14/605 , A61P3/04 , A61P3/10
CPC分类号： C07K14/575 , A61K38/00 , C07K14/605
-
公开(公告)号：EP2552471A1
公开(公告)日：2013-02-06
申请号：EP11711424.9
申请日：2011-03-23
CPC分类号： C07K14/605 , A61K38/00 , C07K14/723
摘要： The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide- 1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analogs with amino acid substitutions introduced to modulate activity for both GIP-R and GLP-1-R and maintain selectivity over Gluc-R.
-
公开(公告)号：EP1753780A1
公开(公告)日：2007-02-21
申请号：EP05749168.0
申请日：2005-05-19
发明人： BOKVIST, Bengt Krister, Lilly Forschung GmbH , CUMMINS, Robert, Chadwick , GLAESNER, Wolfgang , GROMADA, Jesper Lindgren, Lilly Forschung GmbH , MAYER, John, Philip , ZHANG, Lianshan , ALSINA-FERNANDEZ, Jorge
IPC分类号： C07K14/575
CPC分类号： C07K14/57563
摘要： The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
-
公开(公告)号：EP4093757A1
公开(公告)日：2022-11-30
申请号：EP21705072.3
申请日：2021-01-21
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.017 秒)
